Mostrar el registro sencillo del ítem
dc.contributor.author | Mateo Pampliega, Isidro | |
dc.contributor.author | Halstead, S.K. | |
dc.contributor.author | Gourlay, D.S | |
dc.contributor.author | Penderis, J. | |
dc.contributor.author | Bianchi, E. | |
dc.contributor.author | Dondi, M. | |
dc.contributor.author | Wessmann, A. | |
dc.contributor.author | Musteata, M. | |
dc.contributor.author | Le Chevoir, M. | |
dc.contributor.author | Martinez-Anton, L. | |
dc.contributor.author | Bhatti, S.F.M. | |
dc.contributor.author | Volk, H. | |
dc.date.accessioned | 2021-11-30T13:50:17Z | |
dc.date.available | 2021-11-30T13:50:17Z | |
dc.date.created | 2021-11 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12080/26318 | |
dc.description.abstract | Objectives: A previous single-country pilot study indicated serum anti-GM2 and anti-GA1 anti-glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort. Materials and Methods: Sera from 175 dogs clinically diagnosed with acute canine polyradiculoneuritis, 112 dogs with other peripheral nerve, cranial nerve or neuromuscular disorders and 226 neurologically normal dogs were screened for anti-glycolipid antibodies against 11 common glycolipid targets to determine the immunoglobulin G anti-glycolipid antibodies with the highest combined sensitivity and specificity for acute canine polyradiculoneuritis. Results: Anti-GM2 anti-glycolipid antibodies reached the highest combined sensitivity and specificity (sensitivity: 65.1%, 95% confidence interval 57.6 to 72.2%; specificity: 90.2%, 95% confidence interval 83.1 to 95.0%), followed by anti-GalNAc-GD1a anti-glycolipid antibodies (sensitivity: 61.7%, 95% confidence interval 54.1 to 68.9%; specificity: 89.3%, 95% confidence interval 82.0 to 94.3%) and these anti-glycolipid antibodies were frequently present concomitantly. Anti-GA1 anti-glycolipid antibodies were detected in both acute canine polyradiculoneuritis and control animals. Both for anti-GM2 and anti-GalNAc-GD1a anti-glycolipid antibodies, sex was found a significantly associated factor with a female to male odds ratio of 2.55 (P=0.0096) and 3.00 (P=0.0198), respectively. Anti-GalNAc-GD1a anti-glycolipid antibodies were more commonly observed in dogs unable to walk (odds ratio 4.56; P=0.0076). Clinical Significance: Anti-GM2 and anti-GalNAc-GD1a immunoglobulin G anti-glycolipid antibodies represent serum biomarkers for acute canine polyradiculoneuritis. © 2021 The Authors. Journal of Small Animal Practice published by John Wiley & Sons Ltd on behalf of British Small Animal Veterinary Association | es_ES |
dc.format | application/pdf | es_ES |
dc.language | eng | es_ES |
dc.rights | CC-BY | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.es | es_ES |
dc.title | Serum anti-GM2 and anti-GalNAcGD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.location | N/A | es_ES |